Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
We investigated in Lewis normotensive rats the effect of coronary artery ligation on the expression of cardiac angiotensin-converting enzymes (ACE and ACE 2) and angiotensin II type-1 receptors (AT 1a -R) 28 days after myocardial infarction. Losartan, olmesartan, or the vehicle (isotonic saline) was administered via osmotic minipumps for 28 days after coronary artery ligation or sham operation. Coronary artery ligation caused left ventricular dysfunction and cardiac hypertrophy. These changes were associated with increased plasma concentrations of angiotensin I, angiotensin II, angiotensin-(1–7), and serum aldosterone, and reduced AT 1a -R mRNA. Cardiac ACE and ACE 2 mRNAs did not change. Both angiotensin II antagonists attenuated cardiac hypertrophy; olmesartan improved ventricular contractility. Blockade of the AT 1a -R was accompanied by a further increase in plasma concentrations of the angiotensins and reduced serum aldosterone levels. Both losartan and olmesartan completely reversed the reduction in cardiac AT 1a -R mRNA observed after coronary artery ligation while augmenting ACE 2 mRNA by approximately 3-fold. Coadministration of PD123319 did not abate the increase in ACE 2 mRNA induced by losartan. ACE 2 mRNA correlated significantly with angiotensin II, angiotensin-(1–7), and angiotensin I levels. These results provide evidence for an effect of angiotensin II blockade on cardiac ACE 2 mRNA that may be due to direct blockade of AT 1a receptors or a modulatory effect of increased angiotensin-(1–7).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733
Self-citationHydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200581200 · Cited by 1,407
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Liu, Y. H., Yang, X. P., Sharov, V. G., Nass, O., Sabbah, H. N., Peterson, E., & Carretero, O. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119360 · Cited by 603
Carey, R. M., & Siragy, H. M. (2003) · Endocrine Reviews · doi:10.1210/er.2003-0001 · Cited by 603
Counterregulatory Actions of Angiotensin-(1-7)
Ferrario, C. M., Chappell, M. C., Tallant, E. A., Brosnihan, K. B., & Diz, D. I. (1997) · Hypertension · doi:10.1161/01.hyp.30.3.535 · Cited by 509
Self-citationRegulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction.
Nio, Y., Matsubara, H., Murasawa, S., Kanasaki, M., & Inada, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117675 · Cited by 435
Schieffer, B., Wirger, A., Meybrunn, M., Seitz, S., Holtz, J., Riede, U. N., & Drexler, H. (1994) · Circulation · doi:10.1161/01.cir.89.5.2273 · Cited by 420
The angiotensin–converting enzyme gene family: genomics and pharmacology
Turner, A. J., & Hooper, N. M. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01994-5 · Cited by 406
Cited by
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
COVID-19 and cardiovascular disease
Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., Rabbani, L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046941 · Cited by 1,738
Grasselli, G., Greco, M., Zanella, A., Albano, G., Antonelli, M., Bellani, G., Bonanomi, E., Cabrini, L., Carlesso, E., Castelli, G., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3539 · Cited by 1,612
Ferrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005) · Circulation · doi:10.1161/circulationaha.104.510461 · Cited by 1,565
Self-citationCOVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., & Wu, J. C. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0413-9 · Cited by 1,409
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection
Verdecchia, P., Cavallini, C., Spanevello, A., & Angeli, F. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.037 · Cited by 1,237
“The possibility that ACE inhibitors and angiotensin II receptor blockers (ARBs) may be discontinued even temporarily, because these drugs appear to increase the expression of ACE2 receptors, the site of viral entry into the human organism, [72-75] is actively debated.”
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5471 · Cited by 1,081
Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics
Gurwitz, D. (2020) · Drug Development Research · doi:10.1002/ddr.21656 · Cited by 802
Renin‐angiotensin system revisited
Fyhrquist, F., & Saijonmaa, O. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01981.x · Cited by 642
Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051417 · Cited by 592
Kakodkar, P., Kaka, N., & Baig, M. (2020) · Cureus · doi:10.7759/cureus.7560 · Cited by 523
Santos, R. A. S., Ferreira, A. J., Verano-Braga, T., & Bader, M. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0341 · Cited by 523
Kuba, K., Imai, Y., Ohto-Nakanishi, T., & Penninger, J. M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.06.003 · Cited by 480
Guo, J., Huang, Z., Lin, L., & Lv, J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016219 · Cited by 464
The emerging role of ACE2 in physiology and disease
Hamming, I., Cooper, M., Haagmans, B., Hooper, N., Korstanje, R., Osterhaus, A., Timens, W., Turner, A., Navis, G., & van Goor, H. (2007) · The Journal of Pathology · doi:10.1002/path.2162 · Cited by 434
Kai, H., & Kai, M. (2020) · Hypertension Research · doi:10.1038/s41440-020-0455-8 · Cited by 426
Myocardial infarction increases ACE2 expression in rat and humans
Burrell, L. M., Risvanis, J., Kubota, E., Dean, R. G., MacDonald, P. S., Lu, S., Tikellis, C., Grant, S. L., Lew, R. A., Smith, A. I., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi114 · Cited by 423
COVID-19 and the elderly: insights into pathogenesis and clinical decision-making
Perrotta, F., Corbi, G., Mazzeo, G., Boccia, M., Aronne, L., D’Agnano, V., Komici, K., Mazzarella, G., Parrella, R., & Bianco, A. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01631-y · Cited by 420
Magleby, R., Westblade, L. F., Trzebucki, A., Simon, M. S., Rajan, M., Park, J., Goyal, P., Safford, M. M., & Satlin, M. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa851 · Cited by 412
Doobay, M. F., Talman, L. S., Obr, T. D., Tian, X., Davisson, R. L., & Lazartigues, E. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00292.2006 · Cited by 406
Mehta, N., Kalra, A., Nowacki, A. S., Anjewierden, S., Han, Z., Bhat, P., Carmona-Rubio, A. E., Jacob, M., Procop, G. W., Harrington, S., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1855 · Cited by 400
Ferrario, C. M., Trask, A. J., & Jessup, J. A. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00618.2005 · Cited by 385
Self-citationACE2, Much More Than Just a Receptor for SARS-COV-2
Samavati, L., & Uhal, B. D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00317 · Cited by 364
Kreutz, R., Algharably, E. A. E.-H., Azizi, M., Dobrowolski, P., Guzik, T., Januszewicz, A., Persu, A., Prejbisz, A., Riemer, T. G., Wang, J.-G., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa097 · Cited by 357
Muralidar, S., Ambi, S. V., Sekaran, S., & Krishnan, U. M. (2020) · Biochimie · doi:10.1016/j.biochi.2020.09.018 · Cited by 346
Angiotensin‐converting enzyme 2 in the brain: properties and future directions
Xia, H., & Lazartigues, E. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05723.x · Cited by 321
Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor
Tallant, E. A., Ferrario, C. M., & Gallagher, P. E. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00941.2004 · Cited by 318
Self-citationPerico, L., Benigni, A., & Remuzzi, G. (2020) · Nephron · doi:10.1159/000507305 · Cited by 305
Zhang, L.-K., Sun, Y., Zeng, H., Wang, Q., Jiang, X., Shang, W.-J., Wu, Y., Li, S., Zhang, Y.-L., Hao, Z.-N., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00235-0 · Cited by 298
Iwai, M., & Horiuchi, M. (2009) · Hypertension Research · doi:10.1038/hr.2009.74 · Cited by 296
“28, 29 Another ARB, losartan, also induced similar changes; however, its dose was 100-fold higher than that of olmesartan, 28 suggesting that this effect of ARB is not a class effect.”
BackgroundCan angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Esler, M., & Esler, D. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002450 · Cited by 296
Current status of potential therapeutic candidates for the COVID-19 crisis
Zhang, J., Xie, B., & Hashimoto, K. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.046 · Cited by 283
ACE2 of the heart: From angiotensin I to angiotensin (1–7)
KEIDAR, S., KAPLAN, M., & GAMLIELLAZAROVICH, A. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.09.006 · Cited by 278
Ocaranza, M. P., Godoy, I., Jalil, J. E., Varas, M., Collantes, P., Pinto, M., Roman, M., Ramirez, C., Copaja, M., Diaz-Araya, G., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000237862.94083.45 · Cited by 273
Hernández Prada, J. A., Ferreira, A. J., Katovich, M. J., Shenoy, V., Qi, Y., Santos, R. A. S., Castellano, R. K., Lampkins, A. J., Gubala, V., Ostrov, D. A., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.108944 · Cited by 271
Angiotensin-Converting Enzyme II in the Heart and the Kidney
Danilczyk, U., & Penninger, J. M. (2006) · Circulation Research · doi:10.1161/01.res.0000205761.22353.5f · Cited by 269
Castrop, H., Höcherl, K., Kurtz, A., Schweda, F., Todorov, V., & Wagner, C. (2010) · Physiological Reviews · doi:10.1152/physrev.00011.2009 · Cited by 269
Furuhashi, M., Moniwa, N., Mita, T., Fuseya, T., Ishimura, S., Ohno, K., Shibata, S., Tanaka, M., Watanabe, Y., Akasaka, H., et al. (2015) · American Journal of Hypertension · doi:10.1093/ajh/hpu086 · Cited by 263
Ferrario, C. M., Jessup, J., Gallagher, P. E., Averill, D. B., Brosnihan, K. B., Ann Tallant, E., Smith, R. D., & Chappell, M. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00675.x · Cited by 259
Self-citationFernandes, T., Hashimoto, N. Y., Magalhães, F. C., Fernandes, F. B., Casarini, D. E., Carmona, A. K., Krieger, J. E., Phillips, M. I., & Oliveira, E. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168252 · Cited by 253
Sarzani, R., Giulietti, F., Di Pentima, C., Giordano, P., & Spannella, F. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2020 · Cited by 86
“In several animal models, both ACE-I and ARB could upregulate ACE2, especially in heart tissue (19, 37, 61), but it is not known to happen in human lungs.”
BackgroundShah, H., Khan, M. S. H., Dhurandhar, N. V., & Hegde, V. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01636-z · Cited by 80
The depressor axis of the renin–angiotensin system and brain disorders: a translational approach
Gironacci, M. M., Vicario, A., Cerezo, G., & Silva, M. G. (2018) · Clinical Science · doi:10.1042/cs20180189 · Cited by 60
Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids
Rahmani, W., Chung, H., Sinha, S., Bui-Marinos, M. P., Arora, R., Jaffer, A., Corcoran, J. A., Biernaskie, J., & Chun, J. (2022) · iScience · doi:10.1016/j.isci.2022.103818 · Cited by 25
Metadata
- Authors
- Ishiyama, Y., Gallagher, P. E., Averill, D. B., Tallant, E. A., Brosnihan, K. B., & Ferrario, C. M.
- Venue
- Hypertension
- Published
- 2004-05
- Volume
- 43
- Issue
- 5
- Pages
- 970-976
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2141108790
- Cited by
- 564
- References
- 28
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.